National Cancer Institute

The U.S. government’s agency for cancer research. Part of @NIH. Engagement ≠ endorsement. Questions about cancer? Reach us here:

[National Cancer Institute @theNCI]

The CCDI Pediatric and AYA Rare Cancer Study is collecting crucial information to help advance understanding and improve outcomes for young people with rare childhood cancers. Learn more and find out if you're eligible to participate: https://t.co/NOoZxHanuO #Data4ChildhoodCancer

[National Cancer Institute @theNCI]

Learn about the four breast cancer molecular subtypes, which are based on combinations of biomarkers and used by doctors to determine treatment plans. Visit https://t.co/wOT9ypBSzJ for more cancer statistics.

[National Cancer Institute @theNCI]

🎉 The NCI Center for Global Health is proud to celebrate a decade of the Affordable Cancer Technologies (ACTs) program! Catch up with @JCOGO_ASCO co-editors Drs. Fabio Moraes and Paul Pearlman at #ASCO26. Learn more about ACTs at https://t.co/fzSfuZMQgt.

[National Cancer Institute @theNCI]

At #ASCO26? Stop by NCI Exhibit Booth #13037 to meet members of our team and learn more about NCI programs, research resources, training opportunities, and initiatives supporting the oncology community.

[National Cancer Institute @theNCI]

A key message from this #ASCO26 discussion: the U.S. remains at the forefront of oncology clinical trials, but increasing global competition is a call for improvement. We are committed to helping, but meaningful progress will require engagement from all stakeholders.

[National Cancer Institute @theNCI]

⏲️Faster clinical trial activation means faster access to innovation. During today’s #ASCO26 panel, @NCIDirector discussed the importance of aligning stakeholders, supporting cancer centers with guidance and incentives, sharing best practices, and partnering across @HHSGov.

[National Cancer Institute @theNCI]

At #ASCO26? Consider attending these discussions today:
🕗 Time to Activation in Oncology Clinical Trials, featuring @NCIDirector
🗣️Survivorship Community of Practice panel with Chief Ashley Wilder Smith of NCI’s Division of Cancer Control and Population Sciences

[National Cancer Institute @theNCI]

Catch two NCI sessions at #ASCO26 this AM, both taking place from 8 - 11.
💡DART (NCI/SWOG S1609) with comprehensive results of dual CTLA-4/PD-1 blockade in rare cancers, and
💡eSyM, reporting overall survival from an ePRO-based symptom management trial. https://t.co/5A6h1mtBmk

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Fantastic discussion @apolo_andrea @theNCI for past/present/future of nectin4. EV pembro success in #bladdercancer also sets up a new world of challenges for resistance & sequencing approaches. @asco #ASCO26 @oncoalert @urotoday

[ASCO @ASCO]

Dr. Anthony Letai delivered @The_NCI Director’s Address during Opening Session at #ASCO26, focusing on NCI’s commitment to the cancer research community, the current environment & key changes & plans to continue supporting researchers, clinicians & patients.

[National Cancer Institute @theNCI]

Closing message from Dr. Letai at #ASCO26: progress in cancer research is a shared effort, and continued partnership across the oncology community will be essential to delivering the next generation of breakthroughs for patients.

[National Cancer Institute @theNCI]

From functional precision medicine and #AI to cancer therapeutic vaccines and prevention initiatives, innovation and collaboration are crucial to improving outcomes for patients. #ASCO26

[National Cancer Institute @theNCI]

Acknowledging the recent delays and uncertainty that have created challenges for investigators and institutions, @NCIDirector cites that his focus is on improving transparency, reducing friction in the system, and helping promising science move forward more efficiently. #ASCO26

[National Cancer Institute @theNCI]

“Stability is the platform — not the goal.” Dr. Letai is discussing efforts to reduce friction across the research ecosystem and improve the speed of moving discoveries from idea to patient. #ASCO26

[National Cancer Institute @theNCI]

“Cancer research advances because of the people in this room.” Opening the session at #ASCO26, @NCIDirector Dr. Anthony Letai is sharing a message focused on stability, transparency, and partnership across the oncology community.

[National Cancer Institute @theNCI]

Join us Saturday at #ASCO26 for the Opening Session beginning at 9:45 AM CDT, featuring the NCI Director’s Address from Dr. Anthony Letai.

Also from 3–6 PM CDT: Oral Abstract Session on TALAPRO-3 in metastatic castration-sensitive prostate cancer. https://t.co/vhv0fPwMrk

[Dr. Anthony Letai @NCIDirector]

At AACR last month, I received many questions about grant applications. Today on @theNCI Bottom Line blog, I’m providing straight answers on where things stand, and what we’re doing to fund the best science as swiftly as possible: https://t.co/yj6CIQXYVb

[Dr. Anthony Letai @NCIDirector]

On my way to Chicago for #ASCO26 and looking forward to a great week of learning, collaboration, and innovation in cancer care. Excited to be back in the Windy City — and yes, a Chicago-style hot dog may be on the agenda too.

[National Cancer Institute @theNCI]

Shape the future of cancer care! Precision in Practice: A Functional Medicine Workshop on July 1-2, 2026 is a free hybrid event aimed at helping move functional precision oncology more quickly from lab to clinic. Don't miss out! 🔗 https://t.co/YknMbCmkZ9

[National Cancer Institute @theNCI]

Recent FDA approvals are expanding treatment options for people newly diagnosed with #MultipleMyeloma. Studies showed the new treatment combinations helped patients go longer without their cancer worsening and improved treatment responses. https://t.co/lIJrcQ43Cw #WBCD